SLC5A2 and glomerulonephritis: SGLT2 inhibitors have been tested primarily in combination with RAS inhibitors; no specific information has been published on the subgroup of patients not treated with RAS inhibitors in the EMPA-KIDNEY trial with glomerulonephritis.